Human hepatocellular carcinoma (HCC) is one of the most serious complications of chronic liver disease and cirrhosis. Even more disturbing is the observation that the average life expectancy from the time of diagnosis is approximately eight to ten months. The incidence of HCC has begun to increase in the United States principally due to the contribution of chronic hepatitis C (HCV) infection. In addition, with the obesity epidemic including Type II diabetes and insulin resistance, the emergence of non-alcoholic steatohepatitis (NASH) has begun to assume a larger role in the pathogenesis of this devastating disease due to the development of cirrhosis, a risk factor for HCC. More recently, there is widespread concern among health care professionals regarding the increase in HCC and the lack of optimal screening techniques that lead to or contribute to early diagnosis and treatment in the hope of improving the prognosis of this almost uniformly fatal disease. Thus, the purpose of this proposal is to validate a new marker that may be useful in the early diagnosis of HCC. In this regard, we have identified by monoclonal antibody (mAb) binding and expression cloning, a cell surface protein marker that is enhanced in HCC tumors. The gene encoding for this protein has been cloned and molecularly identified as aspartyl (asparaginyl) (?-hydroxylase (HAAH) which appears to be highly expressed in most (>90%) hepatitis B (HBV) and HCV related HCC. Furthermore, this protein appears to be present in serum of such patients. Thus, we have established immunoassays to detect C and N terminal fragments as well as full length HAAH in serum using recombinant proteins as standards. Because this enzyme is expressed on the cell surface, we have recently developed human scFv and IgG antibodies directed against the various region of the molecule. These reagents will be used in biodistribution studies to target tumors in murine models of human HCC. Evidence will be presented to support the hypothesis that HAAH gene is a novel biomarker for HCC since expression appears to be highly associated with the pathogenesis of the disease. We plan to do the following.
Specific Aim 1. Validate HAAH as a biomarker for HCC.
Specific Aim 2. Further characterize human scFv fragments and IgG anti-AAH antibodies. It is likely that these new mAb based assays will be useful for the early detection of HCC and human anti-HAAH antibodies may be employed as targeting reagents for the specific detection of HCC in the liver.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA123544-04
Application #
7821319
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Wagner, Paul D
Project Start
2007-08-17
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
4
Fiscal Year
2010
Total Cost
$238,467
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Huang, Chiung-Kuei; Aihara, Arihiro; Iwagami, Yoshifumi et al. (2016) Expression of transforming growth factor ?1 promotes cholangiocarcinoma development and progression. Cancer Lett 380:153-62
Huang, Chiung-Kuei; Iwagami, Yoshifumi; Aihara, Arihiro et al. (2016) Anti-Tumor Effects of Second Generation ?-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. PLoS One 11:e0150336
Iwagami, Yoshifumi; Huang, Chiung-Kuei; Olsen, Mark J et al. (2016) Aspartate ?-hydroxylase modulates cellular senescence through glycogen synthase kinase 3? in hepatocellular carcinoma. Hepatology 63:1213-26
Chung, Waihong; Kim, Miran; de la Monte, Suzanne et al. (2016) Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett 370:1-9
Shapiro, Jason M; Chung, Waihong; Ogawa, Kosuke et al. (2016) Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase. PLoS One 11:e0165227
Tomimaru, Yoshito; Mishra, Sasmita; Safran, Howard et al. (2015) Aspartate-?-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine 33:1256-66
Rand, Danielle; Derdak, Zoltan; Carlson, Rolf et al. (2015) X-ray Scatter Imaging of Hepatocellular Carcinoma in a Mouse Model Using Nanoparticle Contrast Agents. Sci Rep 5:15673
Dong, Xiaoqun; Lin, Qiushi; Aihara, Arihiro et al. (2015) Aspartate ?-Hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget 6:1231-48
Rand, Danielle; Walsh, Edward G; Derdak, Zoltan et al. (2015) A highly sensitive x-ray imaging modality for hepatocellular carcinoma detection in vitro. Phys Med Biol 60:769-84
Aihara, Arihiro; Huang, Chiung-Kuei; Olsen, Mark J et al. (2014) A cell-surface ?-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology 60:1302-13

Showing the most recent 10 out of 34 publications